×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Press Release

View printer-friendly version
VIDEO from Medialink and Amgen: New Survey Highlights Growing Concern About Risk of Infection and Emerging Antibiotic Resistance in Cancer Patients
--Amgen, CDC Foundation and CDC Partner to Launch Three-Year Initiative to Improve Infection Control in Vulnerable Cancer Patient Population
THOUSAND OAKS, Calif., May 27, 2009 /PRNewswire via COMTEX/ -- Amgen (Nasdaq: AMGN) today announced the results of a national Harris Interactive, Inc. survey indicating that the vast majority of oncologists, and infectious disease (ID) specialists are highly concerned about the negative impact infection may have on treatment outcomes, as well as emerging antibiotic resistance in chemotherapy patients.

See video from Amgen at: http://inr.mediaseed.tv/Amgen_36611/

To help raise awareness of the risks and impact of infections in cancer patients, Amgen is joining forces with the Centers for Disease Control (CDC) Foundation, and the Divisions of Healthcare Quality and Promotion and Cancer Prevention and Control at CDC on a three-year initiative to provide resources and educational tools to help cancer patients, their caregivers and healthcare professionals.

Survey Result Highlights:

Infections among chemotherapy patients are fairly common.

* Nearly one in four patients surveyed (24 percent) had an infection in the last 12 months while receiving chemotherapy treatment. Of these patients:

-- 61 percent had more than one infection;

-- Virtually all took at least a week to recover; 22 percent reported taking four or more weeks to recover;

-- 52 percent had to go the emergency room due to an infection;

* ID specialists report seeing an average of 36 chemotherapy patients with an infection in a typical month.

Antibiotic resistance is a growing concern.

* Nearly all ID specialists (91 percent) report being very or extremely concerned about emerging antibiotic resistance in cancer patients.

* More than half of all patients (51 percent) are extremely or very concerned about antibiotic resistance.

Physicians are concerned about the impact of infections in cancer patients.

* 87 percent of ID specialists are extremely or very concerned about the impact of infections on overall outcomes for chemotherapy patients, including overall survival and disease-free survival.

* Nearly half of cancer patients are not even aware that chemotherapy puts them at greater risk for an infection.

Registered journalists can access video, audio, text, graphics and photos for free and unrestricted use at http://www.mediaseed.tv.

05NY09-0055

SOURCE Medialink; Amgen